Clinical Trial Detail

NCT ID NCT02196181
Title Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Dabrafenib + Trametinib

Age Groups: adult

Additional content available in CKB BOOST